Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies
Status:
Completed
Trial end date:
2020-12-19
Target enrollment:
Participant gender:
Summary
This study is evaluating the safety and preliminary efficacy of BGB-3111 in combination with
BGB-A317 in participants with B-cell lymphoid malignancies.